Recent patents on anti-infective drug discovery | 2019

Identification of quinolone and colistin resistance genes in Escherichia coli strains isolated from mucosal samples of patients with colorectal cancer and healthy subjects.

 
 
 
 
 

Abstract


INTRODUCTION\nAntibiotic resistance and extensive use of antibiotics is one of the major causes of failure in antibiotic treatment. The purpose of this study was to investigate antibiotic resistance patterns and to identify resistance genes of quinolones and colistin in Escherichia coli. There are very few patents on E. coli isolated from colorectal cancer. So, this study demonstrated that some bacteria resistant to ciprofloxacin are not present resistance genes. As well as, new patterns for E. coli are presented for samples of patients with colorectal cancer.\n\n\nMATERIALS AND METHODS\nOf the three healthy, inflammatory bowel diseases (IBD) and colorectal cancer groups, 40 E. coli strains isolated after confirmation by biochemical and molecular methods. The susceptibility of isolates to antibiotics was investigated using disk diffusion test. After deoxyribonucleic acid (DNA) extraction, polymerase chain reaction (PCR) was used to identify genes encoding resistance to ciprofloxacin (qnr A, qnr B) and colistin (mcr-1).\n\n\nRESULTS\nThe results showed that E. coli isolates from colorectal cancer patients had the highest resistance to piperacillin (67.5%), ceftazidime (47.5%), and cefepime (42.5%). Also, E. coli strains isolated from IBD patients showed resistance to antibiotic ceftazidime 13%. More than 95% of E. coli strains isolated from healthy people were susceptible to antibiotics. Based on the results, 18 (15%) E. coli strains were showed resistance to ciprofloxacin. The qnr A gene was detected in 61.11% isolate; however qnr B was detected in 9 (50%). Isolates resistant to colistin were not observed.\n\n\nCONCLUSION\nThese findings indicate increased resistance of E. coli to ciprofloxacin in comparison with prior studies. Further research in this field will increase our knowledge and more effective exposure to the antibiotic resistance of the pathogenic microorganisms.

Volume None
Pages None
DOI 10.2174/1574891X14666190611125951
Language English
Journal Recent patents on anti-infective drug discovery

Full Text